[Gastrointestinal side effects of apremilast : Characterization and management]. / Gastrointestinale Beschwerden unter Apremilast : Charakterisierung und Management.
Hautarzt
; 70(5): 354-362, 2019 May.
Article
en De
| MEDLINE
| ID: mdl-30937481
ABSTRACT
Apremilast is an oral inhibitor of phosphodiesterase-4 (PDE4) that is licensed for the second-line treatment of psoriasis and psoriatic arthritis. Data from several phase III clinical trials and real-world studies showed a good benefit-risk profile, with diarrhea and nausea as the most common adverse events. Diarrhea and nausea most frequently occurred during the first month of treatment. In most cases, they were mild or moderate in severity and tended to resolve over time with continued dosing and without intervention. In this review we summarize available data on gastrointestinal side effects of apremilast in patients with psoriasis and psoriasis arthritis and provide practical strategies for managing these symptoms.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Psoriasis
/
Talidomida
/
Artritis Psoriásica
/
Antiinflamatorios no Esteroideos
/
Inhibidores de Fosfodiesterasa 4
/
Enfermedades Gastrointestinales
Límite:
Humans
Idioma:
De
Revista:
Hautarzt
Año:
2019
Tipo del documento:
Article